低卵巢储备女性ICSI治疗前每日低剂量hCG雄激素预处理八周的效果
这项前瞻性自身对照单中心研究纳入20名低卵巢储备女性,比较连续8周每日注射260 IU重组hCG后与对照周期的IVF/ICSI结局。主要终点卵泡输出率未增加(P=0.8),但研究周期获卵数显著高于对照周期(4.7 vs 3.2,P=0.01),刺激时间更长(P=0.05)。样本量小,获卵数非主要终点,需更大研究证实。
要点
- 8周每日260 IU重组hCG预处理未提高低卵巢储备女性的卵泡输出率(P=0.8)。
- 研究周期获卵数显著高于对照周期(4.7 vs 3.2,P=0.01)。
- 研究周期刺激时间较对照周期更长(P=0.05),样本量小,需更大研究证实。
核心结论
- 长期低剂量重组hCG给药可能增加低卵巢储备女性IVF/ICSI的获卵数,但需更多研究才能得出确切结论。
研究设计与样本
- 前瞻性自身对照非盲单中心研究,纳入20名女性作为自身对照,于2021年1月至2021年7月在丹麦哥本哈根大学医院Rigshospitalet进行。
- 参与者接受两个相同的连续IVF/ICSI治疗周期(对照周期和研究周期),中间隔约8周(两个月经周期)每日注射260 IU重组hCG。
- 对照周期采用全胚冷冻策略,两个IVF/ICSI周期均采用固定GnRH拮抗剂方案,每日300 IU重组FSH,从刺激第5-6天起使用GnRH拮抗剂0.25 mg。
主要发现
- 卵泡输出率(hCG触发日>16 mm卵泡数除以基线2-10 mm窦卵泡数)在8周hCG预处理后未增加(P=0.8)。
- 研究周期平均获卵数显著高于对照周期,分别为4.7(2.8) vs 3.2(1.7)(P=0.01)。
- 研究周期刺激时间较对照周期更长(P=0.05),尽管两周期使用相同的hCG触发标准和触发日三个最大卵泡直径相似(P=0.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 样本量小,且获卵数不是主要终点。
- 需要更大规模的研究来证实这一发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does 8 weeks of continuous low-dose hCG administration increase the proportion of antral follicles that reach the preovulatory state during ovarian stimulation (OS) in women with low ovarian reserve? SUMMARY ANSWER: The proportion of antral follicles (2-10 mm) that reached the preovulatory state did not increase. WHAT IS KNOWN ALREADY: The administration of androgens prior to OS might upregulate FSH receptor (FSHR) expression on granulosa cells, making follicles more responsive to exogenous FSH stimulation during OS. LH and hCG stimulate the local follicular androgen synthesis in theca cells and may be used as an endogenous androgen priming method. Exogenous priming by testosterone and dehydroepiandrosterone (DHEA) have been shown to increase the number of retrieved oocytes and live birth rate but the studies are small, and their use is associated with side effects. STUDY DESIGN, SIZE, DURATION: A prospective, paired, non-blinded single-center study including 20 women serving as their own controls conducted between January 2021 and July 2021 at The University Hospital Copenhagen Rigshospitalet, Denmark. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants underwent two identical consecutive IVF/ICSI treatments, a Control cycle and a Study cycle, separated by ∼8 weeks (two menstrual cycles) of daily injections of 260 IU recombinant hCG (rhCG). A freeze-all strategy was applied in the Control cycle. Both IVF/ICSI cycles were performed in a fixed GnRH antagonist protocol using a daily dose of 300 IU recombinant FSH (rFSH) and GnRH antagonist 0.25 mg from stimulation days 5-6. MAIN RESULTS AND THE ROLE OF CHANCE: Follicular output rate, defined as the number of follicles >16 mm on hCG trigger day divided by the antral follicle count (2-10 mm) at baseline, did not increase after 8 weeks of hCG priming (P = 0.8). The mean number of oocytes retrieved was significantly higher after the hCG priming being 4.7 (2.8) vs 3.2 (1.7) in the Study and Control cycle, respectively (P = 0.01). The duration of stimulation was longer in the Study versus the Control cycle (P = 0.05), despite the use of identical hCG trigger criterion and similar diameters of the three biggest follicles on hCG trigger day in the two cycles (P = 0.9). LIMITATIONS, REASONS FOR CAUTION: The sample size was small, and the number of oocytes retrieved was not the primary endpoint. Larger studies are needed to confirm this finding. WIDER IMPLICATIONS OF THE FINDINGS: Long-term, low-dose rhCG administration may increase the number of oocytes retrieved during IVF/ICSI in women with low ovarian reserve, but more research is needed before firm conclusions can be drawn. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by an unrestricted grant from Gedeon Richter. A.P. reports personal consulting fees from PregLem SA, Novo Nordisk A/S, Ferring Pharmaceuticals A/S, Gedeon Richter Nordics AB, Cryos International, and Merck A/S outside the submitted work and payment or honoraria for lectures from Gedeon Richter Nordics AB, Ferring Pharmaceuticals A/S, Merck A/S, and Theramex and Organon & Co. Grants to the institution have been provided by Gedeon Richter Nordics AB, Ferring Pharmaceuticals A/S, and Merck A/S and receipt of equipment by the institution from Gedeon Richter Nordics AB is reported. The remaining authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT04643925.
引用
- Friis Wang N, Bogstad JW, Pors SE, et al. Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve. Hum Reprod. 2023. PMID: 36721920. doi:10.1093/humrep/dead012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。